Novartis agreed to buy biotechnology company Avidity in a deal valued at $12 billion, making it the Swiss drugmaker's biggest acquisition in more than a decade and adding several potential blockbuster treatments as generic competition looms for its current top-sellers. Sam Fazeli of Bloomberg Intelligence has more.
View Comments
Novartis Agrees $12 Billion Biotech Deal for Avidity
Published 1 week ago
Oct 27, 2025 at 8:37 AM
Neutral
Auto